Innate's Lirilumab In Limbo After Phase II Combo Failure

Bristol-Myers Squibb and Innate Pharma's anti-KIR monoclonal antibody lirilumab has failed to show efficacy in a combination trial with Opdivo in head and neck cancer – further development of the doublet treatment in solid tumors now seems unlikely.

Swing
Future of Innate/BMS's lirilumab hangs in the balance • Source: Shutterstock

Just before Thanksgiving, Innate Pharma SA announced its anti-KIR (killer-cell immunoglobulin-like receptor) drug lirilumab, which is licensed to Bristol-Myers Squibb Co., failed to provide clear evidence of benefit in a combination trial with Opdivo. It is further bad news for Innate as the drug also failed to demonstrate efficacy in a monotherapy trial earlier this year.

Innate's stock was down around 40% on Nov. 23, falling on the Paris stock exchange from more than €8 per...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D